In the past few years, the preservation of cells and tissues has gained importance, owing to the increasing use of biobanks to understand the genetic causes of disease, resulting in a more individualized approach to healthcare. Furthermore, growing investments by pharmaceutical companies in research & development to engage in drug discovery & development activities for incorporating various new and innovative drugs to treat diseases like Alzheimer's disease, Parkinson's disease, cancer, and diabetes.
The process of freezing tissues and cells includes various methods such as deep freezing, cryopreservation, and freeze-drying among others which aim to preserve biological material's viability, make it biologically inert, stop ice crystal formation, and reduce genetic alteration, and guard against contamination-related loss. In addition, cells are frozen using various medium or serum types. The two most frequently used alternatives are glycerol & dimethyl sulfoxide (DMSO), which are used in a mixture of serum and medium for the preservation process.
Furthermore, if properly frozen, the cells & tissues can survive for more than ten years. These tissues can be frozen using well-proven techniques, and in the presence of cryoprotective chemicals, they can be kept frozen for an extended amount of time at a temperature of -14°C (6.8°F).
Four processes are used by cryoprotectants to protect slowly frozen cells and tissue:
-
Reducing high salt concentrations
-
Decreasing cell shrinkage
-
Reducing the fraction of the solution that is frozen
- Minimizing intracellular ice formation.
These days, the most dependable, user-friendly, and secure options are ready-to-use products like CryoStem. These kinds of solutions have the following advantages: they are protein-free, compatible with a variety of media, ideal for freezing cells cultivated in both feeder- as well as feeder-free conditions, and they have a high recovery effectiveness for human cells. Additionally, methylcellulose and DMSO are used in CryoStem in place of serum, removing the dangers connected with animal serum and serum-derived products.
According to the paper published in The Journal Communications Biology, in September 2022, human heart tissue that had been kept in a subfreezing, supercooled state for one to three days was effectively resurrected by UC Berkeley researchers. The findings also point to isochoric supercooling as a potential method for preserving donor tissue in the future and creating an opportunity in the area of medical research.
Segments
|
Details
|
Type
|
Cell Preservation (Mammalian Cells & Others (Microorganisms and Plant Cells); Tissue Preservation (Blood, Bone, Soft Tissues, Skin and Others)
|
Product
|
Equipment (freezers, thawing systems, refrigerators, storage systems, and others); Bio preservation media; Software
|
Application
|
Therapeutics, research & development, drug discovery, and others.
|
End user
|
Biobank; Hospitals; Others
|
Region
|
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
|
Major companies operating in the cell & tissue preservation market include Thermo Fisher Scientific, Inc., Lonza, BD, MerckKGaA, Cytiva, Agilent Technologies, Inc., Avantor, Inc., FUJIFILM Irvine Scientific, BioLifeSolutions Inc., AMSBIO, Princeton CryoTech, STEMCELL Technologies Inc., LGC SeraCare, Corning Incorporated, and CellGenix GmbH.